Ghent University Academic Bibliography

Molecular and cellularf unctions of CTLA-4

Samya Van Coillie (UGent) , Bartosz Wiernicki (UGent) and Jie Xu

(2020) REGULATION OF CANCER IMMUNE CHECKPOINTS: MOLECULAR AND CELLULAR MECHANISMS AND THERAPY. 1248. p.7-32

Synthetic rhamnose glycopolymer cell-surface receptor for endogenous antibody recruitment

Ruben De Coen (UGent) , Lutz Nuhn, Chamani Perera, Maria Arista-Romero, Martijn Risseeuw (UGent) , Alec Freyn, Raffael Nachbagauer, Lorenzo Albertazzi, Serge Van Calenbergh (UGent) , David A. Spiegel, et al.

(2020) BIOMACROMOLECULES. 21(2). p.793-802

Add to list

Journal Article
A1
open access

Three decades of messenger RNA vaccine development

Rein Verbeke (UGent) , Ine Lentacker (UGent) , Stefaan De Smedt (UGent) and Heleen Dewitte (UGent)

(2019) NANO TODAY. 28.

Add to list

Transiently thermoresponsive acetal polymers for safe and effective administration of Amphotericin B as a vaccine adjuvant

Simon Van Herck (UGent) , Lien Van Hoecke (UGent) , Benoit Louage (UGent) , Lien Lybaert (UGent) , Ruben De Coen (UGent) , Sabah Kasmi (UGent) , Aaron P Esser-Kahn, Sunil A David, Lutz Nuhn, Bert Schepens (UGent) , et al.

(2018) BIOCONJUGATE CHEMISTRY. 29(3). p.748-760

Add to list

Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety

Kevin Van der Jeught, Stefaan De Koker, Lukasz Bialkowski, Carlo Heirman, Patrick Tjok Joe, Federico Perche, Sarah Maenhout, Sanne Bevers, Katrijn Broos, Kim Deswarte (UGent) , et al.

(2018) ACS NANO. 12(10). p.9815-9829

Add to list

Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist

Lutz Nuhn (UGent) , Lien Van Hoecke (UGent) , Kim Deswarte (UGent) , Bert Schepens (UGent) , Yupeng Li, Bart Lambrecht (UGent) , Stefaan De Koker (UGent) , Sunil A David, Xavier Saelens (UGent) and Bruno De Geest (UGent)

(2018) BIOMATERIALS. 178. p.643-651

Add to list

Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses

Lutz Nuhn (UGent) , Stefaan De Koker (UGent) , Sandra Van Lint (UGent) , Zifu Zhong (UGent) , João Portela Catani (UGent) , Francis Combes (UGent) , Kim Deswarte (UGent) , Yupeng Li, Bart Lambrecht (UGent) , Stefan Lienenklaus, et al.

(2018) ADVANCED MATERIALS. 30(45).

Add to list

Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo

Reinhart Speeckaert (UGent) and Nanja van Geel (UGent)

(2017) EXPERIMENTAL DERMATOLOGY. 26(7). p.630-634

Add to list

Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells

Laura Wayteck (UGent) , Ranhua Xiong (UGent) , Kevin Braeckmans (UGent) , Stefaan De Smedt (UGent) and Koen Raemdonck (UGent)

(2017) JOURNAL OF CONTROLLED RELEASE. 267. p.154-162

Add to list

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Philippe Aftimos, Christian Rolfo, Sylvie Rottey (UGent) , Fritz Offner (UGent) , Dominique Bron, Marie Maerevoet, Jean-Charles Soria, Mahan Moshir, Torsten Dreier, Luc Van Rompaey, et al.

(2017) CLINICAL CANCER RESEARCH. 23(21). p.6411-6420

Academic Bibliography

Molecular and cellularf unctions of CTLA-4

Synthetic rhamnose glycopolymer cell-surface receptor for endogenous antibody recruitment

Three decades of messenger RNA vaccine development

Transiently thermoresponsive acetal polymers for safe and effective administration of Amphotericin B as a vaccine adjuvant

Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety

Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist

Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses

Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo

Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Contents

Support

Contact